IDEXX Laboratories (NASDAQ: IDXX) is one of 256 publicly-traded companies in the “MED PRODS” industry, but how does it weigh in compared to its rivals? We will compare IDEXX Laboratories to related companies based on the strength of its analyst recommendations, earnings, risk, institutional ownership, profitability, dividends and valuation.
This table compares IDEXX Laboratories and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|IDEXX Laboratories Competitors||-650.97%||-110.55%||-14.91%|
87.1% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 52.2% of shares of all “MED PRODS” companies are held by institutional investors. 2.8% of IDEXX Laboratories shares are held by company insiders. Comparatively, 15.3% of shares of all “MED PRODS” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for IDEXX Laboratories and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|IDEXX Laboratories Competitors||1080||4484||8386||269||2.55|
IDEXX Laboratories currently has a consensus target price of $190.67, suggesting a potential downside of 6.87%. As a group, “MED PRODS” companies have a potential upside of 8.91%. Given IDEXX Laboratories’ rivals higher probable upside, analysts clearly believe IDEXX Laboratories has less favorable growth aspects than its rivals.
Risk and Volatility
IDEXX Laboratories has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, IDEXX Laboratories’ rivals have a beta of 0.96, meaning that their average share price is 4% less volatile than the S&P 500.
Earnings & Valuation
This table compares IDEXX Laboratories and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|IDEXX Laboratories||$1.97 billion||$263.14 million||69.64|
|IDEXX Laboratories Competitors||$3.71 billion||$128.14 million||-3.30|
IDEXX Laboratories’ rivals have higher revenue, but lower earnings than IDEXX Laboratories. IDEXX Laboratories is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
IDEXX Laboratories beats its rivals on 7 of the 13 factors compared.
About IDEXX Laboratories
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.